Holen Sie sich die Stockscreener-App
3.12
0.00%
0.00
Handel nachbörslich:
3.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com
Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.
Esperion to be acquired by ARCHIMED - The Pharma Letter
MSN Money - MSN
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - The AI Journal
What's Going On With Esperion Therapeutics Stock On Monday? - Benzinga
Jefferies Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.28 - Moomoo
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.16 - Moomoo
Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5 - marketscreener.com
ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan - StocksToTrade
Penny Stocks To Watch TodayMay 2nd - MarketBeat
ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout - timothysykes.com
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $3.16 to $3.28 - Moomoo
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Esperion Therapeutics, Inc. $ESPR is AIGH Capital Management LLC's 10th Largest Position - MarketBeat
HC Wainwright & Co. downgrades Esperion Therapeutics (ESPR) - MSN
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Benzinga
Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion - Law360
Piper Sandler Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
Archimed to take Esperion Therapeutics private in $1.1 billion deal - WHTC
Esperion Stock Surges On ARCHIMED’s $1.1 Billion Buyout — What Shareholders Get Next - TechStock²
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpShould You Buy? - MarketBeat
The Biotech Growth Trust plc Archimed to acquire Biog Portfolio Company, Esperion Therapeutics. - marketscreener.com
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
Esperion agrees to $1.1 billion ARCHIMED buyout - TipRanks
Investors Buy High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - MarketBeat
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - BioPharma Dive
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - ChartMill
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal - Yahoo Finance
Cantor Fitzgerald Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
H.C. Wainwright Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
Ann Arbor drugmaker to be acquired by French investor - Crain's Detroit Business
Archimed to Acquire Biotech Growth Trust Portfolio Co Esperion for $1 Billion - marketscreener.com
H.C. Wainwright cuts Esperion stock rating on Archimed buyout By Investing.com - Investing.com Canada
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by HC Wainwright to Neutral - MarketBeat
An unknown funds, managed by ArchiMed SAS entered into a definitive agreement to acquire Esperion Therapeutics, Inc.. - marketscreener.com
ESPR Rallies As Royalty Deal Fuels Corstasis Expansion - StocksToTrade
Archimed to acquire Esperion Therapeutics for $1 billion By Investing.com - Investing.com Canada
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
ESPR Stock In Focus As Royalty Deal Fuels Corstasis Acquisition - timothysykes.com
Esperion Stock Pops On Billion-Dollar ARCHIMED Buyout - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs - Stock Titan
Esperion Therapeutics: Board of Directors Has Unanimously Approved the Transaction >ESPR - Moomoo
ARCHIMED to acquire Esperion for up to $1.1 billion - Investing.com
Esperion Therapeutics to Be Acquired by ARCHIMED in Up to $1.1 Billion Transaction, Shareholders to Receive $3.16 Per Share in Cash - Quiver Quantitative
Esperion to be Acquired by ARCHIMED - The Manila Times
ARCHIMED to acquire Esperion for up to $1.1 billion By Investing.com - Investing.com Canada
Archimed to take Esperion Therapeutics private for up to $1.1 billion - marketscreener.com
Archimed privatizará Esperion Therapeutics por hasta 1.100 millones de dólares - TradingView
ESPR Stock Quote Price and Forecast - CNN
ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics (ESPR) Expected to Announce Earnings on Thursday - MarketBeat
#1 Most Undervalued Stock to BUY: 40% Growth, 4x Forward Earnings, and Massive Upside Potential - Moomoo
ESPREsperion Therapeutics Inc Stock Price and Quote - Finviz
Rumor Desk: ESPERION PARTNERSHIP WITH BIG PHARMA IN THE WORKS. Stock Price Will Double - Moomoo
Esperion Therapeutics prices $75M public offering - MSN
This $2 Stock Profitable This Year $9 Price Target Analysts See As M&A Target. Has Yearly Billion Dollar Revenue Stream Potential - Moomoo
Esperion Therapeutics soars amid vague takeover speculation - MSN
0.67%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):